SAT1 and cancer: ChIP‐seq analysis in various cancer cell models further indicated the significant enrichment of TP53 at the SAT1 promoter (Figure 5D), and ChIP‐qPCR exhibited the enhanced binding of TP53 to the SAT1 promoter, with a further increase upon the L14‐8 treatment (Figure 5E).